Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors.

Autor: Cunningham KN; Department of Dermatology, Tufts Medical Center, Boston, MA, USA. kaitlynne.cunningham@downstate.edu., Rosmarin D; Department of Dermatology, Tufts Medical Center, Boston, MA, USA.
Jazyk: angličtina
Zdroj: American journal of clinical dermatology [Am J Clin Dermatol] 2023 Mar; Vol. 24 (2), pp. 165-186. Date of Electronic Publication: 2023 Jan 30.
DOI: 10.1007/s40257-022-00752-6
Abstrakt: Vitiligo is a chronic autoimmune disease characterized by loss of pigment of the skin, affecting 0.5-2% of the population worldwide. It can have a significant impact on patients' quality of life. In recent years, there has been significant progress in our understanding of the pathogenesis of vitiligo. It is believed that vitiligo develops due to a complex combination of genetics, oxidative stress, inflammation, and environmental triggers. Conventional treatments include camouflage, topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids, phototherapy, and surgical procedures, with the treatment regimen dependent on the patient's preferences and characteristics. With increased understanding of the importance of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway in the pathogenesis of vitiligo, treatment has expanded to include the first US FDA-approved cream to repigment patients with vitiligo. This review summarizes our understanding of the major mechanisms involved in the pathogenesis of vitiligo and its most common available treatments.
(© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
Databáze: MEDLINE
Externí odkaz: